AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02680392 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsed and Continuous Radiofrequency
Description: Preoperative pulsed radiofrequency of the saphenous nerve and Continuous radiofrequency of the genicular nerves of the knee joint.~The saphenous nerve will be approached at the adductor canal and it will be treated with Pulsed RF for 4 minutes at 42 Celsius degrees. Ropivacaine 0.5% 10ml with Dexamethasone 10mg will be injected after the RF.~The Genicular terminal branches of the sciatic and femoral nerves will be treated with Continuous RF for 3 min at 80 Celsius degrees and then with 2 ml of Ropivacaine 0.5% and 10 mg of Methylprednisolone to each nerve (5 in total) A sham catheter in the mid-thigh will be placed for patients in the RF group, infusing Normal Saline 0.9% and simulating a Continuous Adductor Canal Block. To blind the investigator to the type of treatment for the postoperative assessment , every solution bag will be prepared by the Pharmacy of the Hospital, covered with a plastic envelope and labeled as Study Solution.
Study NCT02680392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Adductor Canal Block
Description: The patients in the Adductor canal group, will have a catheter for peripheral nerve block inserted under strict asepsis in the adductor canal under ultrasound guidance, and will receive for postoperative analgesia a 48-h continuous infusion of Ropivacaine 0.2% at 8 ml/hour The patients will receive, intraoperatively 10 mg of Dexamethasone i.v.~To blind the investigator who will do the postoperative assessment to the type of treatment, every solution bag will be prepared by the Pharmacy of the Hospital, covered with a plastic envelope and labeled as Study Solution. It will be always possible to crack the code and find out to which group the patient belongs
Study NCT00297830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Drug is administered through 5 mg intravenous infusion over 20 minutes
Study NCT01495364 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBS10
Description: dosage = 10 or more million CD34+ cells via intracoronary infusion
Study NCT01495364 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo
Study NCT03825575 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT)
Description: A 3 week treatment period with a total of 8 treatments of 1 hour over the sacral spinal cord
Study NCT03516942 — intervention group
Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03326583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patiromer
Description: Patiromer will be orally self-administered by participants.
Study NCT01551472 — intervention group
Intervention type: DEVICE
Intervention: 3DKnee™ System with Vitamin E UHMWPE Tibial Inserts
Description: This device is part of a total knee replacement system utilized in treating patients who are candidates for primary cemented total knee arthroplasty or revision arthroplasty where bone loss is minimal and the collateral ligaments are intact. It is intended to aid the surgeon in relieving the patient of knee pain and restoring knee joint function.
Study NCT03841526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon RTU Injection With Insulin Pump Reduction
Description: 0.15 mg injection with 50% pump reduction
Study NCT03516942 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04549831 — intervention group
Intervention type: GENETIC
Intervention: Massive parallel sequencing of host genome
Description: Massive parallel sequencing and genotyping of host genome of individuals infected with SARS-CoV-2 and showing different clinical outcomes from asymptomatic to severely affected patients in order to identify the genetic determinants of severe COVID-19 and the genetic protective factors.
Study NCT03578536 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Recovery Rapids
Description: This project utilizes a new gaming system technology called Recovery Rapids. The game is custom-made by Games That Move You, LLC and runs on an XBOX platform with motion input via a Kinect system.
Study NCT03749785 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular carbohydrate feeding
Description: 60 ml of water with 5 g sucrose given every 5 minutes 14 times up until 70 minutes followed by 5 g sucrose after 75 minutes in a 250 ml solution
Study NCT03749785 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single carbohydrate bolus
Description: 60 ml of water given every 5 minutes 14 times up until 70 minutes followed by 75 g sucrose after 75 minutes in a 250 ml solution
Study NCT03841526 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle for Glucagon RTU Injection With Insulin Pump Reduction
Description: vehicle injection with 50% pump reduction
Study NCT02345720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon - PVP (multi-focal)
Description: The investigational contact lens must be worn at least six hours daily.
Study NCT01619410 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: Linezolid 600 mg every 12 hours for 7 days
Study NCT01619410 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: Clindamycin 300 mg po every 6 hours for 7 days
Study NCT00643188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: Radiofrequency ablation of atrial fibrillation
Study NCT00643188 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: The best medical treatment according to the ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult and the ACC/AHA/ESC 2006 Guidelines for Management of Patients with Atrial Fibrillation.
Study NCT01607762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Type= exact number, unit= mg, number= 1, form= tablet, route= oral administration. A single oral dose of a 1-mg risperidone tablet will be administered after an overnight fast.
Study NCT01607762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone
Description: Type= exact number, unit= mg, number= 3, form= tablet, route= oral administration. A single oral dose of a 3-mg paliperidone tablet will be administered after an overnight fast.
Study NCT00454740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin succinate
Description: Oral
Study NCT04286269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Based Intervention
Description: Participants assigned to MBI will receive a total of 1.5 hours of music intervention 5-6 sessions per week. Music will be alternating: 30 minutes on and 30 minutes off and will be played when the subject is awake to cue pacification and initiate the sleep process. Music will be delivered through headphones using an MP3 player.
Study NCT04286269 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment
Description: Participants assigned to the control group will have the same treatment as the MBI group, but with no sound played through the headphones.
Study NCT00529789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine
Description: 20 - 120 milligrams (mg) every day, once-daily (QD), by mouth (PO) for 30 weeks; If patient is ≤40 kilograms (kg), initial dose is 20 mg, then titrated up. If patient is >40 kg, initial dose is 30 mg, then titrated up.
Study NCT05101954 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Concentrated Growth Factors (CGF)
Description: Concentrated Growth Factors membrane will be laid in the implant cavity. Bone graft material will be applied to fill the empty parts of the socket.
Study NCT05101954 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-Rich Fibrin (PRF)
Description: Platelet-Rich Fibrin (PRF) membrane will be laid in the implant cavity. Bone graft material will be applied to fill the empty parts of the socket.
Study NCT03750214 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biop Colposcopy System
Description: The procedure stages:~1. Scanning of the cervix - the cervix is scanned using the micro colposcope probe unit, to produce a total of 51 micro-images and one macro image from the panoramic camera.~2. Colposcopy exam - during the standard colposcopy exam, the doctor acquires a panoramic image of the cervix with the digital colposcope.~3. A questionnaire completed by the subject after the Biop procedure, with regards to any unusual sensations or events experienced during the procedure.~4. A questionnaire completed by the user after the Biop procedure, with regards to system usage~5. Image Registration analysis
Study NCT02337036 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic
Description: Taking blood samples for an Pharmacokinetic of tacrolimus in Paediatric Liver Transplant Patients treated with tacrolimus
Study NCT02337036 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic
Description: Pharmacogenetic study
Study NCT02337036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: These Patients are treated with tacrolimus after the Liver Transplantation
Study NCT04768712 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight bearing aerobic exercise
Description: Weight bearing aerobic exercise three times per week.
Study NCT04011813 — intervention group
Intervention type: OTHER
Intervention: Hypotaurine : antioxidant and osmoregulator
Description: Hypotaurine has protective effects on sperm motility, capacitation and acrosome reaction and reduces apoptotic markers.~Hypotaurine (50mM) was added in density gradient centrifugation, washing and cryopreservation media washing and cryopreservation media before spermatozoa freezing
Study NCT03488745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IntelliCare + Phone Coaching
Description: IntelliCare is composed of 13 separate, native apps. Each app targets a specific aspect of mental health (e.g., reducing worry, increasing social support, tracking negative thoughts). The apps are available to the public in both Android and iPhone stores. Participants will be asked to try two new IntelliCare apps every week, for 7 weeks. Phone coaching will occur at Day 0, before using any of the apps, and the third week of app usage.
Study NCT01869179 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community of Voices choir program
Description: Attend weekly choir sessions for 12 months at the Senior Center. All choir sessions will include activities that focus on cognitive, psychosocial, and physical engagement components Choir sessions will last 90 minutes each with a 10 minute break. Take part in 3-4 informal choir concerts.
Study NCT01869179 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wait-list control group
Study NCT03753984 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Description: In both arms will be applied Low-level laser therapy and induced muscle fatigue.
Study NCT01995903 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI(magnetic resonance imaging)
Description: Subjects with amyotrophic lateral sclerosis and lower neuron motor skills and healthy subjects will undergo an MRI(magnetic resonance imaging)scans of the brain to assess neurologic condition. The brain scans will take approximately 60 minutes to complete.
Study NCT01995903 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MRI(magnetic resonance imaging)
Description: Subjects with amyotrophic lateral sclerosis and lower neuron motor skills and healthy subjects will undergo an MRI(magnetic resonance imaging)scans of the brain to assess neurologic condition. The brain scans will take approximately 60 minutes to complete.
Study NCT02462759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nusinersen
Description: Administered by intrathecal injection.
Study NCT02462759 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: Small needle prick on the lower back at the location where the IT injection is normally made.
Study NCT03262831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: The yoga practice, Gentle Hatha and Restorative Yoga, will be based on protocols that have been found to decease fatigue and weight gain by helping the participant gain insight in recognizing stress responses and ways to relax
Study NCT00590122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parcopa
Description: at subjects current stable dose of comparator
Study NCT00590122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carbidopa-levodopa (Sinemet)
Description: at subjects current stable dose
Study NCT04077424 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone-High Dose Quadrivalent
Description: Seasonal influenza vaccination with FDA approved vaccines for this age group.
Study NCT04077424 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluad
Description: Adjuvanted (MF59) inactivated influenza vaccine
Study NCT04077424 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Flublock
Description: Recombinant hemagglutinin vaccine
Study NCT03536481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ensartinib capsules (test product)
Description: Test product(T)：100mg ensartinib capsules manufactured by Betta Pharmaceuticals
Study NCT03536481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ensartinib capsules (reference product)
Description: Reference product(R)：100mg ensartinib capsules manufactured by Catalent Pharma Solutions
Study NCT03262831 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: * Baseline and end of treatment~* To evaluate change in inflammatory markers (CRP, IL-6, and TNF)
Study NCT01370941 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Drug A Chymosin
Description: Five drops of chymosin is added to ½ a liter of milk. This is to be consumed during breakfast.
Study NCT01370941 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Drug B: Placebo
Description: B: Five drops of placebo (water) is added to ½ a liter of milk. This is to be consumed during breakfast.
Study NCT00241176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Baseline Visit 2: Subjects btw 25-50kg start on 1.25mg/day, btw 50-70kg start on 2.5mg/day, greater than 70kg start on 5mg/day Visit 3: Titrated based on YGTSS \& CGI-TS ratings at investigator discretion. Subjects who show evidence of response (reduction in CGI-TS by 1-2 points) may remain on same dose. Subjects who show no response may increase as follows: btw 25-50kg increase to 2.5mg/day, btw 50-70kg increase to 3.75mg/day, greater than 70kg increase to 7.5mg/day Visit 5: Subjects who show no response may increase as follows: btw 25-50kg increase to 3.75mg/day, btw 50-70kg increase to 5mg/day, greater than 70kg increase to 10mg/day Visit 6: Subjects who show no response may be increase as follows: btw 25-50kg increase to 5mg/day, btw 50-70kg increase to 7.5mg/day, greater than 70kg increase to 12.5mg/day Visit 7: Subjects who how no response may be increase as follows: btw 25-50kg increase to 7.5mg/day, btw 50-70kg increase to 10mg/day, greater than 70kg increase to 15mg/day
Study NCT00128024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lipid-lowering treatment
Study NCT04601207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis Preparation
Description: Dosed as a single oral dose
Study NCT06053918 — intervention group
Intervention type: OTHER
Intervention: additional follow-up extension at home
Description: additional interview when leaving the sector, and the extension of follow-up of the patient at home
Study NCT05948514 — intervention group
Intervention type: OTHER
Intervention: The complications related to central venous access device
Description: The complications related to central venous access device were collected when occurs : from time of catheter insertion, until first complication, or removal for another type of catheter, or until death.
Study NCT04601207 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabis Preparation
Description: Dosed as a single oral dose
Study NCT02220803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Acetazolamide, 250mg tablets, will be administrated as multiple doses. Dosing of acetazolamide will be up-titrated during 3 days according to manufacturer instruction and titration scheme of the study. Maximum daily dosage is 750 mg (equivalent of 3 tablets/daily). Evening medication should be taken 2 hours before bedtime. The total length of Acetazolamide treatment will be 4 weeks (2x2) including 3 days of titration phase of the drug.
Study NCT02220803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Acetazolamide, 250mg tablets, will be administrated as multiple doses. Dosing of acetazolamide will be up-titrated during 3 days according to manufacturer instruction and titration scheme of the study. Maximum daily dosage is 750 mg (equivalent of 3 tablets/daily). Evening medication should be taken 2 hours before bedtime. The total length of Acetazolamide treatment will be 4 weeks (2x2) including 3 days of titration phase of the drug.
Study NCT02220803 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasal Continuous Positive Airway Pressure (nCPAP)
Study NCT02180204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Description: Tenecteplase 0.25 mg/kg IV - Maximum 25 mg
Study NCT02180204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Description: Alteplase 0.9 mg/kg IV - Maximum: 90 mg
Study NCT00090961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Study NCT00090961 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: educational intervention
Study NCT00090961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: supervised exercise program
Study NCT01687543 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L. plantarum 299 and L. plantarum 299v (+maltodextrin)
Description: A suspension of Lactobacillus plantarum 299 and Lactobacillus plantarum 299v together with maltodextrin is distributed to the patients twice a day.
Study NCT01687543 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: A suspension of maltodextrin (as placebo control) is distributed to the patients twice a day.
Study NCT03262831 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood draw
Description: * Baseline and end of treatment~* To evaluate change in inflammatory markers (CRP, IL-6, and TNF)
Study NCT03262831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FACT-G questionnaire
Description: * 7 statements that other people with breast cancer have said are important, the patient is to circle or mark one number per line to indicate the response as it applies in the last 7 days~* Answers range from 0=not at all to 4=very much
Study NCT03262831 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FACT-G questionnaire
Description: * 7 statements that other people with breast cancer have said are important, the patient is to circle or mark one number per line to indicate the response as it applies in the last 7 days~* Answers range from 0=not at all to 4=very much
Study NCT03262831 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Weight measurement
Description: -Weight will be taken at baseline, on day 1 of each cycle, and the end of treatment
Study NCT03262831 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Weight measurement
Description: -Weight will be taken at baseline, on day 1 of each cycle, and the end of treatment
Study NCT03262831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recent Physical Activity Questionnaire
Description: -To assess physical activity, the RPAQ will be completed at baseline and at the end of treatment.
Study NCT03262831 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Recent Physical Activity Questionnaire
Description: -To assess physical activity, the RPAQ will be completed at baseline and at the end of treatment.
Study NCT03262831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NHANES Food Questionnaire
Description: -To assess diet, the NHANES Food Questionnaire will be completed at baseline and at the end of treatment.
Study NCT03262831 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NHANES Food Questionnaire
Description: -To assess diet, the NHANES Food Questionnaire will be completed at baseline and at the end of treatment.
Study NCT01881412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone
Description: During discharge, the study MD/nurse informs the family that the child has been randomized to the inhaled corticosteroid (ICS) group, and will be prescribed fluticasone to help control the asthma. The families preferred pharmacy is determined and a prescription for a fluticasone multi-dose inhaler (MDI) provided. Dosing follows the NHLBI asthma guidelines for low dose ICS in this age group (88 mcg administered twice per day, dispense one inhaler, 3 refills). In addition to standard asthma discharge instructions, the family receives specific instructions for ICS administration, possible side effects of medication use, and distinction between controller and quick-relief rescue medications. Parents are instructed to discuss with their primary care provider the length of ICS use.